Episode Details
Back to Episodes
UTHR's Q1 Misses, But Pipeline Shines
Description
United Therapeutics Q1 earnings missed Wall Streets predictions due to seasonal dips and operational hiccups, but the company remains optimistic about its pipeline, with positive late-stage trial results for ralinepag and Tyvaso. Tyvaso DPI is gaining traction, and management hints at doubling revenue in the next few years. The company is focusing on a patient-first approach for IPF drugs and is working on new formulations like RALDPI for future growth.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/d43739d45f15836d